Intravitreal Injections in Thailand Your guide to cost, top specialists & hospitals

Our partner centres have dedicated retinal departments with OCT suites, fluorescein angiography, widefield imaging, and injection rooms with full sterile protocols. All three anti-VEGF agents are stocked and available for immediate use. These are active retinal treatment centres with high patient volumes.

Our partner retinal specialists manage large cohorts of anti-VEGF patients and follow evidence-based treat-and-extend protocols. They adjust treatment intervals based on OCT data, not calendar schedules, which reduces the total injection burden while maintaining disease control.

For patients who start treatment in Thailand and continue at home, our team prepares a comprehensive treatment report including OCT images, injection history, and recommended treatment interval. This allows straightforward handover to your local retinal specialist. For patients who prefer to return to Thailand for treatment, visits can be coordinated to include multiple injections during a single trip.

In wet AMD, anti-VEGF therapy can prevent further vision loss and improve vision in some patients^3,2. In diabetic macular oedema, most patients achieve stable or improved central vision with consistent treatment. In retinal vein occlusion, anti-VEGF significantly reduces macular oedema and improves acuity. These are landmark results backed by decades of clinical trial data.

Treatment response varies by condition, severity at presentation, and treatment adherence. Patients treated early, before significant structural damage occurs, have the best outcomes. Your retinal specialist will discuss expected outcomes based on your OCT findings and diagnosis. Consistent adherence to the injection schedule is the single most important factor in long-term visual preservation.

Intravitreal injections in Thailand typically cost between $800 and $1,450 per injection, depending on the agent used. Bevacizumab is the most affordable option. Ranibizumab and aflibercept cost more but are purpose-designed for intravitreal use with the strongest regulatory approval. The price includes the consultation, OCT assessment, injection, and immediate post-injection monitoring.

Each session includes the retinal specialist consultation, OCT imaging assessment, the anti-VEGF medication itself, sterile injection procedure, facility fee, and immediate post-injection pressure check. For patients on ongoing treatment, package pricing for multiple injections during a single trip may be available.

The anti-VEGF agent is the main cost variable. Bevacizumab costs significantly less per injection than ranibizumab or aflibercept. For patients needing 6–12 injections per year, the choice of agent has a major impact on annual treatment cost. Clinical efficacy data supports all three agents for most indications.

Pricing varies by the complexity and scope of the procedure. Typical ranges at our partner hospitals in Thailand:

• Anti-VEGF injection (bevacizumab): $800–$950. Most affordable anti-VEGF option, widely used off-label.
• Anti-VEGF injection (ranibizumab or aflibercept): $950–$1,200. FDA-approved agents with robust clinical-trial data.
• Steroid injection (dexamethasone implant): $1,100–$1,450. Slow-release steroid for inflammatory or steroid-responsive macular oedema.

Exact pricing is confirmed after your consultation and treatment plan are finalised.

Intravitreal injections in Thailand cost 40–60% less per injection than in the US ($2,000–$3,200), Australia (A$1,850–A$3,050), and UK (£1,600–£2,800). Over a year of treatment involving 6–8 injections, the savings can amount to thousands of dollars.

Before anti-VEGF therapy became standard, retinal laser was the main option. Focal or grid laser photocoagulation still has a role in some cases of diabetic macular oedema or vein occlusion, and photodynamic therapy is occasionally used for select AMD. Laser seals or destroys leaking vessels rather than switching off the signal that drives them, so it can leave small permanent blind spots, often needs anti-VEGF alongside it, and for wet AMD it no longer matches injections on vision outcomes. A slow-release steroid implant is another route for inflammatory or steroid-responsive oedema, though it carries its own risk of raised eye pressure and cataract.

Simply watching and waiting is not a safe alternative for active wet AMD, diabetic macular oedema, or vein occlusion. These conditions leak and scar over weeks, and vision lost to that damage usually does not come back. Delaying treatment to avoid the needle tends to cost more sight than the injection ever risks, which is why every major guideline now puts anti-VEGF first for these diagnoses.

For the conditions on this page, intravitreal anti-VEGF therapy is the evidence-based first-line treatment, backed by decades of trial data, and that is what the rest of this page covers. Where laser or a steroid implant adds value, a retinal specialist usually combines it with injections rather than using it instead.

There are no flying restrictions after intravitreal injections. You can fly the same day or the next day. The procedure does not involve gas tamponade or incisions that are affected by cabin pressure. A brief follow-up before departure confirms the eye is stable.

Virtually none. Normal activities including reading, screen use, exercise, and daily routines can resume immediately. Avoid rubbing the eye for a day or two. Swimming can resume after at least 3 days¹. This is one of the least disruptive medical procedures in ophthalmology.

Each injection provides temporary disease control, typically 4–16 weeks depending on the agent and your treatment response. Anti-VEGF therapy manages the disease rather than curing it. With consistent treatment and OCT-guided scheduling, most patients maintain stable vision long-term. A small subset of patients achieve disease stability allowing extended intervals between injections, but most patients on anti-VEGF therapy require ongoing maintenance dosing indefinitely. Lifelong monitoring is the norm.

Intravitreal injections are done under topical anaesthesia, which means numbing eye drops rather than any needle to put you to sleep or numb the area from inside. You are fully awake and resting back in the chair throughout, and the drops take effect within a couple of minutes so the surface of the eye loses sensation before anything begins. Your retinal specialist performs the injection while a nurse assists, and the whole thing is over in seconds.

There is no general anaesthetic and no sedation needed, so there is no pre-operative fasting and no anaesthetist involved. Before the injection the surface is cleaned with an antiseptic and a small clip gently holds the eyelids open so you do not have to worry about blinking. You will be asked to look in a particular direction, which keeps your eye still and steady at the right moment, and the injection goes into the white of the eye, away from your line of sight.

The part people dread most, seeing the needle, does not happen: it comes in from the side and out of focus, so you are not watching it approach. With the eye numbed you feel brief pressure rather than a sharp sting, and that fades quickly once the drops wear off over the next hour. Afterwards the eye can feel a little gritty or watery for a few hours, which is normal and settles on its own.

Yes. The injection technique and sterile protocol are identical worldwide. Thailand's retinal centres follow rigorous infection-control standards including povidone-iodine antisepsis, sterile draping, and single-use instruments. Our partner ophthalmologists are fellowship-trained retinal specialists who perform high volumes of injection therapy. With single-use instruments and standardised antisepsis, the risk of injection-related infection stays very low.

Anti-VEGF agents have been used intravitreally for nearly two decades, with extensive long-term safety data. The main concerns, endophthalmitis and sustained pressure elevation, are rare and well managed with proper technique and monitoring. The benefit for sight-threatening conditions consistently outweighs the small procedural risk.

Delaying or skipping injections allows the underlying disease to become active again. Fluid reaccumulates, blood vessels leak, and further vision loss can occur. Adherence to the recommended treatment schedule is important. If you cannot travel to Thailand for every injection, arrange continuation with a retinal specialist at home. Consistent treatment produces the best long-term results.

For a single injection, 3–5 days covers the consultation, OCT assessment, injection, and follow-up. If you are starting a loading course (three to four monthly injections, depending on the agent), you can schedule the first during your Thailand trip and continue the rest at home, or plan a longer stay to complete the series.

Each injection session includes retinal specialist consultation, OCT imaging assessment, the anti-VEGF injection, sterile procedure room, post-injection monitoring, and care coordination. Your coordinator can build a schedule that includes multiple injections during a single extended trip if preferred.

Most patients need ongoing injections for months to years. Starting in Thailand and continuing with a retinal specialist at home is a common and practical approach. Your Thai retinal surgeon provides a detailed report and treatment plan for coordinated handover. Some patients return to Thailand periodically for injection batches to benefit from lower per-injection costs.